# Innoviva Inc. (INVA) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $20.93, market value $1.5 billion.

## Valuation
- **P/E (trailing): 4.9×** (5-yr avg 14.6×, 3-yr avg 20.5×). Innoviva Inc. trades at 4.9× trailing earnings, well below its own five-year average of 14.6×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 9.5×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.01**. A PEG of 0.01 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.4×**. Each dollar of revenue is priced at 3.4×.
- **Price / book: 1.2×**. The shares trade at 1.2× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 20.4%**. The inverse of the P/E: 20.4% of the price is earned each year.

## Profitability
- **Gross margin: 72.2%**. Innoviva Inc. keeps 72.2% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 36.9%**. 36.9% of revenue is left after running the business, an exceptional level.
- **Net margin: 65.9%**. 65.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 23.1%**. 23.1% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 14.6%**. Return on all capital, debt included, is 14.6%.
- **Return on assets: 21.8%**. Each dollar of assets produces 21.8% of profit.

## Growth
- **Revenue growth (1 yr): 14.7%** (3-yr 7.5%/yr, 5-yr 4.1%/yr). Revenue grew 14.7% over the last year, against 4.1% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 816.7%** (3-yr 11.7%/yr, 5-yr 10.3%/yr). Earnings per share rose 816.7%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -1.0%/yr**. Free cash flow has compounded at -1.0% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 0.22**. Debt is 0.22 times equity: a conservative balance sheet.
- **Current ratio: 14.64** (quick 14.64). Current assets cover the next year's liabilities 14.64 times.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Innoviva Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 15.5%** (YTD 5.2%, 3-mo 1.2%). The shares are up 15.5% over twelve months including dividends.
- **From 52-week high: -16.8%** (17.1% above the low). Trading 17% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): -0.03** (volatility 27%). Beta of -0.03 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=INVA · Page: https://foliofundamentals.com/stocks/inva

Not investment advice.